This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Therrell Jr, B. L.
Right arrow Articles by Gunn, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Therrell Jr, B. L.
Right arrow Articles by Gunn, S.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 101 No. 4 April 1998, pp. 583-590

Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia

Received Jan 2, 1997; accepted Aug 28, 1997.

Bradford L. Therrell Jr*, Sheri A. BerenbaumDagger , Valerie Manter-KapankeDagger , Jennifer Simmank*, Kristina KormanDagger , Linda Prentice§, Jose Gonzalezparallel , and Sheila Gunn

From the * Bureau of Laboratories, Texas Department of Health, Austin, Texas; Dagger  Department of Behavioral and Social Sciences, Southern Illinois University School of Medicine, Carbondale, Illinois; § Bureau of Children's Health, Texas Department of Health, Austin, Texas; parallel  Children's Medical Center of Dallas, Dallas, Texas; and  Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

Objective.  To assess results of newborn screening for 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH) in Texas over 6 years of screening 1.9 million infants.

Methods.  In 1989, CAH was incorporated into the ongoing Texas Newborn Screening Program, which requires two screens on each newborn. 17-Hydroxyprogesterone was assayed, without extraction, by radioimmunoassay of blood collected from heel sticks onto filter paper collection cards. Infants with elevated levels of 17-hydroxyprogesterone were referred for evaluation, and those considered to have CAH were studied with respect to disease characteristics. Data were collected by pediatric endocrinologists using standardized forms that included type of CAH, results of laboratory tests, treatment regimen, disease symptoms and signs, and, for girls, degree of genital virilization.

Results.  The incidence of classic CAH in Texas is 1:16 008, with a ratio of salt-wasting to simple-virilizing of 2.7:1. A majority of infants detected were undiagnosed until screened, despite signs of salt-wasting or ambiguous genitalia. It was difficult to differentiate salt-wasting from simple-virilizing CAH in infants who were identified before the onset of adrenal insufficiency or electrolyte abnormalities. A substantial number of infants with nonclassic (NC) CAH also were detected. Not all infants were detected on the initial screen; 14% of infants with classic CAH and 87% with NC CAH were detected on the second routine screening test.

Conclusions.  Our findings confirm the benefits of newborn screening for CAH and the importance of a second screening test, and suggest that programs for newborn CAH screening must consider complex issues in diagnosis and treatment. These results also confirm that CAH is a continuum of disorders, rather than a disorder with discrete subtypes. In addition, the difficulties in differentiating CAH subtypes in newborns, and thus deciding appropriate treatment, and the high incidence of NC CAH suggest that standard diagnostic criteria and treatment regimens for CAH may need modification. Where screening exists, physicians will encounter more cases of CAH than in the past.

Key words: congenital adrenal hyperplasia, newborn screening, 21-hydroxylase deficiency, 17-hydroxyprogesterone.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
H. J. van der Kamp, C. G. M. Oudshoorn, B. H. Elvers, M. van Baarle, B. J. Otten, J. M. Wit, and P. H. Verkerk
Cutoff Levels of 17-{alpha}-Hydroxyprogesterone in Neonatal Screening for Congenital Adrenal Hyperplasia Should Be Based on Gestational Age Rather Than on Birth Weight
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3904 - 3907.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
F. Votava, D. Torok, J. Kovacs, D. Moslinger, S. M Baumgartner-Parzer, J. Solyom, Z. Pribilincova, T. Battelino, J. Lebl, H. Frisch, et al.
Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia
Eur. J. Endocrinol., June 1, 2005; 152(6): 869 - 874.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. G. Riepe, S. Tatzel, W. G. Sippell, J. Pleiss, and N. Krone
Congenital Adrenal Hyperplasia: The Molecular Basis of 21-Hydroxylase Deficiency in H-2aw18 Mice
Endocrinology, June 1, 2005; 146(6): 2563 - 2574.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. Keen-Kim, J. B. Redman, R. U. Alanes, M. M. Eachus, R. C. Wilson, M. I. New, J. M. Nakamoto, and R. G. Fenwick
Validation and Clinical Application of a Locus-Specific Polymerase Chain Reaction- and Minisequencing-Based Assay for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)
J. Mol. Diagn., May 1, 2005; 7(2): 236 - 246.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Olgemoller, A. A. Roscher, B. Liebl, and R. Fingerhut
Screening for Congenital Adrenal Hyperplasia: Adjustment of 17-Hydroxyprogesterone Cut-Off Values to Both Age and Birth Weight Markedly Improves the Predictive Value
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5790 - 5794.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. W. Speiser and P. C. White
Congenital Adrenal Hyperplasia
N. Engl. J. Med., August 21, 2003; 349(8): 776 - 788.
[Full Text] [PDF]

Home page
 PediatricsHome page
A. Nordenstrom, A. Wedell, L. Hagenfeldt, C. Marcus, and A. Larsson
Neonatal Screening for Congenital Adrenal Hyperplasia: 17-Hydroxyprogesterone Levels and CYP21 Genotypes in Preterm Infants
Pediatrics, October 1, 2001; 108(4): e68 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
J. L. King, J. M. Naber, R. J. Hopkin, D. R. Repaske, L. Bailey, and N. D. Leslie
Antenatal Corticosteroids and Newborn Screening for Congenital Adrenal Hyperplasia
Arch Pediatr Adolesc Med, September 1, 2001; 155(9): 1038 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Kovacs, F. Votava, G. Heinze, J. Solyom, J. Lebl, Z. Pribilincova, H. Frisch, T. Battelino, and F. Waldhauser
Lessons From 30 Years of Clinical Diagnosis and Treatment of Congenital Adrenal Hyperplasia in Five Middle European Countries
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2958 - 2964.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. A. Brosnan, P. G. Brosnan, J. M. Swint;, J. L. Frias, L. S. Levine, S. E. Oberfield, S. Pang, and J. Silverstein
Analyzing the Cost of Neonatal Screening for Congenital Adrenal Hyperplasia
Pediatrics, May 1, 2001; 107(5): 1238 - 1238.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. l’Allemand, V. Tardy, A. Grüters, D. Schnabel, H. Krude, and Y. Morel
How a Patient Homozygous for a 30-kb Deletion of the C4-CYP 21 Genomic Region Can Have a Nonclassic Form of 21-Hydroxylase Deficiency
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4562 - 4567.
[Abstract] [Full Text]

Home page
 PediatricsHome page
Section on Endocrinology and Committee on Genetics
Technical Report: Congenital Adrenal Hyperplasia
Pediatrics, December 1, 2000; 106(6): 1511 - 1518.
[Abstract] [Full Text]

Home page
 PediatricsHome page
Serving the Family From Birth to the Medical Home. Newborn Screening: A Blueprint for the Future - A Call for a National Agenda on State Newborn Screening Programs
Pediatrics, August 1, 2000; 106(2): 389 - 422.
[Full Text]

Home page
 Endocr. Rev.Home page
P. C. White and P. W. Speiser
Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Endocr. Rev., June 1, 2000; 21(3): 245 - 291.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. A. Berenbaum, S. C. Duck, and K. Bryk
Behavioral Effects of Prenatal Versus Postnatal Androgen Excess in Children with 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 727 - 733.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. D. Wijesuriya, G. Zhang, A. Dardis, and W. L. Miller
Transcriptional Regulatory Elements of the Human Gene for Cytochrome P450c21 (Steroid 21-Hydroxylase) Lie within Intron 35 of the Linked C4B Gene
J. Biol. Chem., December 31, 1999; 274(53): 38097 - 38106.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
P. G. Brosnan, C. A. Brosnan, S. F. Kemp, D. B. Domek, D. H. Jelley, P. R. Blackett, and W. J. Riley
Effect of Newborn Screening for Congenital Adrenal Hyperplasia
Arch Pediatr Adolesc Med, December 1, 1999; 153(12): 1272 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Ferenczi, M. Garami, E. Kiss, M. Pék, M. Sasvári-Székely, C. Barta, M. Staub, J. Sólyom, and G. Fekete
Screening for Mutations of 21-Hydroxylase Gene in Hungarian Patients with Congenital Adrenal Hyperplasia
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2369 - 2372.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. F. L. Meyer-Bahlburg
What Causes Low Rates of Child-Bearing in Congenital Adrenal Hyperplasia?
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1844 - 1847.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Nordenström, A. Thilén, L. Hagenfeldt, A. Larsson, and A. Wedell
Genotyping Is a Valuable Diagnostic Complement to Neonatal Screening for Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency
J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1505 - 1509.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Fitness, N. Dixit, D. Webster, T. Torresani, R. Pergolizzi, P. W. Speiser, and D. J. Day
Genotyping of CYP21, Linked Chromosome 6p Markers, and a Sex-Specific Gene in Neonatal Screening for Congenital Adrenal Hyperplasia
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 960 - 966.
[Abstract] [Full Text]